RecruitingNCT06526065

Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)

Molecular Mechanisms in Malignant Lymphoma- Predict

Sponsor

University Medical Center Goettingen

Enrollment

500 participants

Start Date

Jun 20, 2024

Study Type

OBSERVATIONAL

Conditions

DLBCL - Diffuse Large B Cell Lymphoma

Summary

The trial aims at the construction and validation of an accurate, affordable and simple prognostic tool to be used in everyday clinical practice, which allows the early and reliable identification of DLBCL patients who have a very high risk of treatment failure following R-CHOP/-like first-line therapy.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria5

Histological diagnosis of DLBCL\&LBCL
Planned treatment with guideline-based first-line therapy
Patient's consent
All genders, Patient age ≥ 18 years
Ability to consent

Exclusion Criteria4

Treatment with R-CHOP/-like regimens already started
Relationship of dependence/ direct employment with the investigator
Active HIV-infection
Presence history of other active cancers (with the exception of basal cell carcinoma of the skin)